erik: if teva isn't successful buying mylan that teva itself becomes a takeover target? david: i think that is highly unlikely. with teva's market rising to where it is, it is a bit too expensive. as we have reported in the past there would be quite a few problems. teva would be a hard deal to do. the release of central government opposition and opposition from the labor union. that would be very difficult. the main idea here is for teva to buy mylan. shareholders for both companies seem to be pressuring management to support this. drew: it is something we have seen and that is probably where the pressure is coming from on this given the culture clash we know about. teva has said they think they could save about $2 billion here. they are already in the middle of a big cost cutting move. the closed 11 plants last year and are looking at 16 more. these are two of the biggest generic drugmakers. mylan makes 1400 and teva makes over 1000. stephanie: seems like a colossal mess. a huge amount of money and a big mess and no one wants to do it. drew: generic business is all abou

mylan for perigo teva for mylan. value creating combination between teva and mylan.se remember it's $82 a share in cash and stock and they say that they remain fully committed to getting that deal done as i pointed out many times, they may be fully committed but there are a great deal of weapons in the arsenal that mylan has to prevent them from being successful. not the least of which is the structure in netherlands. and mylan has yet it even respond to teva's offer. typically we would get some sort of response from mylan. remember it came out prior to the actual offer and said it wasn't interested. before teva even made it. >>> shares of juniper networks are soaring are up on soaring earnings. juniper's new ceo after his predecessor was force to resign in november following a board review of his conduct with an unnamed client. joining us, the ceo of juniper networks. good morning to you. it looks like the quarter was all about demand for the cloud, cable and the european telcos. >> you're right. we had a solid q 1 quarter. think that's a testament to the fact that

teva up as well after teva made an unsolicited bid to acquire mylan to create a generics powerhouse theld over. $82 a share. 50/50 cash and stock offer from teva. mylan as a result of being incorporated in the netherlands has certain provisions that basically allow it to say no and succeed in saying no should it choose not to engage here. that's the simplest way i can put it. it has to do with dutch takeover law. the presence of the stick dink which are tough to beat. teva will be able to entertain shareholders of mylan with this strong offer. and get them to perhaps vote down any perrigo deal should that get to a vote. in the shares of mylan, you've got the likes of paulson and senator. abbott can't vote. they can't force them to do a deal. abbott is a large shareholder. they sold a unit to abbott and abbott took stock. abbott doesn't have to vote in favor of a perrigo deal. >> harley-davidson is the top loser at the moment of the open. there is a brutality price form within motorcycles. harley is warning its sales growth isn't going to be 4% to 6% but more 2% to 4%. sales under a huge

teva and mylan compete in similar markets. teva is the number one generic drug maker.wo in the u.s.. antitrust authorities will have a close look at this. that is a major obstacle. mylan shareholders, mylan's chairman has already publicly said that he does not see the deal as a good fit for mylan. teva's ceo will have to do quite a bit of convincing. there are quite a few obstacles. mark: thanks, david. david in tel aviv. anna: you are looking at a live shot of london. equities open up and around 10 minutes' time. trading pretty flat for the start of this morning's trading session. the nikkei 225 closed above 1000 for the first time in 15 years. let's see what that does to european trade. after the break, we will look at what is driving trade today. ♪ anna: we are just a few minutes away from the start of european equity trade. tesco will be one of the stocks to watch for sure. it just recorded the biggest loss in its history. caroline is here. let's remind everyone the scale. caroline: they are bigger than has been expected. kitchen sinking it is what everyone was say

that teva teva has done as well.lan seems to have rejected this deal before it is even been tabled. elliott: yes, quite an unusual move from island. -- from mylan. this was not something that was totally unexpected. in a statement put out last week by the executive chairman, he said we have studied the potential combination of mylan and teva for some time and we believe it is clear that such a combination is without sound industrial logic or cultural fit. he was referring to many overlaps between the two companies. the more you overlap, the more opportunity there is for cost reduction. teva wants to be the undisputed champion generic, to boost profits and it is also mindful that it's biggest selling drug a treatment for multiple sclerosis, that is facing generic competition as early as this year. coincidentally, just last week the u.s. announced the first generic competitor to teva's's drug. mark: greece moving public funds to its central bank to meet imf debt repayment deadlines. ♪ . mark: welcome back to "countdown

mylan and teva is a deal potentially in the works.k: this is something analysts had been exciting for a while. scarlett: yes, there has been a lot of movement among pharmaceutical companies. one that people were looking at was mylan. this was something that had been discussed or speculated upon in the markets. nevertheless, you see when reporting comes across in the headlines at the water, you still get an immediate reaction the share price. mark: scarlet fu joining us from the breaking news desk. let three cap one of the other top stories we are following at this hour. more breaking news. we are learning that people familiar with the matter say that staff attorneys of the justice department's antitrust division are nearing a recommendation to block comcast bid to buy time warner cable. the people who asked not to be identified telling bloomberg that attorneys who are investigating comcast 45.2 billion dollar proposal to create a nationwide cable giant are leaning against the merger out of concerns that consumers would be harmed. and

the shares of mylan soared 8% and the shares for teva were higher. this could change the landscape of the industry but there is no guarantee anything about it will be easy. megan tirrell has more. >> another day and another deal in the drug industry. neva's offer for rival mylan comes on the heels of mylan's offer to buy periggo, a move some expected to be defensive. it contributed to deal activity among drug companies. >> you have to be big or you will get acquired. >> but mylan is not expected to go easily.y rejected the idea of a merger with teva saying it will be a cultural clash and could raise anti-trust concerned and teva dismissed that today and said they could close the deal by the end of the year. the israeli company said they could create a transformative generic drug company with revenue of $30 billion and there could be $2 billion in cost cuts it anticipated. teva makes the multiple sclerosis medi copaxone which brings in billions of dollars a year and could seek growth through acquisition. >> teva clearly feels they need to do something

and lastly that mylan, too, is in play vis-a-vis teva.llenge almost for anyone and i don't mean that in a malicious way but the challenges that teva and its senior management and board have had, you know are not new, that's been going on for quite some time. any company would have to deal with that. i think, too, the market probably you know has been wanting teva to do something substantial for yitquite some time. if not now, when and what? >> what about the roll of pfizer? there some speculation on trading blogs it might get involved. mylan is -- >> it's a really good question. here's my point of view on that and this is just my point of view. people have talked about pfizer splitting into three pieces right? my point of view was three years ago that wasn't possible. now the company has positioned itself so that's possible. when they bought his para, i took that as a tell they will likely split the established products mature brands from innovative core. you follow that logic further, right, established products business, right, would ma

teva could make a that as soon as today.said 9 month revenues rose the most in 11 years. sky benefited from record growth in germany and austria. francine: brady dougan's last set of resultss. he ad to zurich to hear from the credit suisse ceo. guy: a possible antitrust suit with gazprom. francine: teva's possible bid for mylan. ♪ francine: welcome to "the pulse," live from london. guy: first quarter numbers beat estimates at credit suisse. the stock is off 3% from the open. to help us understand what is going on, let us go to zero equipped manus cranny -- let us go to the zurich with manus cranny. manus: the word capital, the problem is going to be capitalized brady dougan goes out the door. 10%, that is a catastrophe when you think that ubs has a capital buffer of 13%. regulators want more capital and the issue will be whether the new ceo can raise capital. the surge in activity did well but when it comes to looking into the numbers, morgan stanley storming. credit suisse nowhere near those levels. my question to brady dou

willie's reserve. ♪ betty: more news on teva and mylan.: this has been speculated upon for a while. we have been reporting that the two were in discussion. teva looking to buy mylan for $82 a share in cash and stock. that would represent a 21% premium to the last close. this is a 50/50 cash offer stock. mylan said it had studied the possibility of a combination with teva and is committed to a standalone strategy. it was unusual for mylan to respond to report that teva was exploring the takeover offer. it wanted to be clear it was not interested in such an offer. teva proposing to by mylan for $82 a share for cash and stock. this deal can be completed by the end of the year of 2015. adding to its adjusted earnings per share approaching 30% by year three. it sees it as accretive to its own earnings. this proposal would not be subject to a financing condition. cash and stock offer to buy mylan for $82 a share. we will keep you posted on other developments. you can see that teva and mylan shares both moving higher on this. betty: very interest

mylan has its own offer from teva on the table which it's rejected.'t come back but sent a letter saying "why you being so mean to us" and then saying "we don't make sense together" and picking on teva and its big practices. >> meg terrill, thank you. a lot of moving parts here. >> i think meg red the subtlety just right. "why are you being so mean to us." now we see teva coming back being a little mean themselves saying "you mischaracterized what was going on there." so we've seen these menage the trios before. it seems to make sense that they're maybe artificially inflated, perrigo saying they're worth more. the last time we saw this multiple bidders, it was all over the map and it turned it the right way to do it is to own all of them. somebody's going home with somebody else. >> oh, really? >> yes, at some point. >> so when we had that hexagon or whatever it was -- >> all of them. >> so are you doing this with these three? >> you know, it's distasteful but i think -- i don't own them yet, i should. i wish i had owned mylan. i think perrigo is okay

teva is based in israel. is incorporated in the netherlands and has a market cap of $33 billion. mylan made an unsolicited bid of almost $29 billion to buy the other company. some are saying that is a trigger for teva to act before mylan becomes bigger. teva and mylan or higher on a day when almost everyone is lower. the deal had been approved by shareholders. another deal may come undone because of regulators. we are talking about comcast and time warner cable. bloomberg is reporting department of justice antitrust lawyers are leaning towards blocking comcast's plan to buy time warner cable. they are lower on the news. they are lower along with the broader market. if you look at other media companies, there are a lot of moving parts. people are saying if comcast does in that buying time warner cable, what does that mean? all of these other stocks are lower in line with the overall weakness in the broader market. alix: thank you. does fracking cause cancer? is fracking bad for us? it is a debate that rages th

up next teva offering $40 billion to buy mylan. it would create the world's biggest generic drugmaker. mylan popping 9%. teva could be in for a nasty battle. the pros will talk it out. >> mylan has a deal to buy perrigo. where does that go? after the bell, amgen yahoo! chipotle and yum brands. those results the second they hit the tape. that's coming up on "closing bell." >>> welcome back. there's a look at some of the earnings that we are waiting for after the bell including names like amgen. a possible shake-up in the generic drug industry. teva offering $40 billion to buy mylan. there's a look at shares of both companies. mylan especially higher on the news. >> not close to the offering price, though, we'll talk about that. the deal faces some serious head winds. meg terrell joins us to fill us in. meg? >> probably the biggest head wind is that mylan doesn't want to be acquired. the company came out preemptively saying there could be cultural clashes and antitrust issues. as you mentioned earlier, it has a bid on the table for p

teva or mylan? because a lot of people are speculating that mylan really just went after perrigo defensively, maybe as just a way to get thatva to raise its offer? >> both teva and mylan would like to see a deal because the business inherently is very volatile. it goes up and down based on how things happen every year with loss of products. so the more the bulk the better. especially when you have one single product at teva and mylan making a lot of the products the more you diversify, the better. i think both need the deal. i think teva might need a little bit more because they've had some management issues in the past, and they probably want to make a statement that they are not going in this direction, in a certain way, but, i think these deals do make a lot of sense, because it allows you to bulk up. it also allows you to go after margins, because you can offset your slower growth by margin grouping. >> brian item. >> hey, fred. it's brian sullivan in los angeles. you know, the interesting thing

great to have you with us. >> tlast for having me. >> i know you cover teva but how likely will tevasuccessful in that the market and the price action is telling us nobody thinks it's going to happen and there's a dutch poison pill which is another obstacle. >> i love to call this the love/hate triangle. what teva is trying to do here is they were the biggest generic company. you have the two titans of the industry, two big generic companies. it doesn't really make sense why you would put two generic companies together because they're so duplicative in what teva would get from mylan. teva is trying to become more of a brand company. they're using mylan as a financial tool to fund what they should have been doing for the last five years which is planning for the expiration of their pat tent. by putting the two companies together you can extract $2 billion in synergies and that would help fund what they should have been doing which is buying more branded drugs to bolster the brand component of their portfolio. >> this sounds like short-term financial engineering then. it's not pipeline

that's when bloomberg reported teva was considering a bid., mylan took the unusual step of publicly rejecting the offer before it even made -- before it was even made. that's a look at the top stories we are following on this tuesday. coming up at two: 55, scarlet fu chats with michael murphy of rose cliff capital as we go on the markets. later, bill gross tells us why he sees bonds is the short of a lifetime. in january, chipotle halted sales of pork at hundreds of its restaurants, saying one of its suppliers was not adhering to its strict standards. just what makes chipotle's pork so special? julie went to iowa to find out. >> imagine a pig farm. you probably think of a scene like this. in iowa, you will see pigs in the pasture, beating at a trough, maybe some chickens alongside scratching in the dirt, and, of course, a big red on. >> the summertime, you got knee-deep alfalfa, a sow laying there, nursing her picks contentedly. julie: this is a network of farms spread across iowa and pennsylvania. in reality, the vast majority of pig farms i

now we finally hear in mylan responding to the bid made for it by teva.g press release, which it fully, completely totally says we have no interest saying it grossly undervalues mylan, and the board unanimously determined that teva's proposal would require shareholders to accept quote, what we believe are low-quality teva shares in exchange for their high-quality mylan shares in a transaction that carries -- and risk. we'll see where it goes. all i pointed out on friday mylan's new bid not much of an improvement on the old bid. we'll see what mylan does today. a couple things to add here on this entire situation, one in particular that has not been reported, or if it has, certainly has not been fully understood by the stock market. that has to do with copaxson a key treatment that of course teva has for multiple sclr rods. the treatment has gone generic, most of the population was migrated by teva to a different formulation. interesting to note that on march 3rd mylan in an interparty's review challenged the remaining patents on copaxson that teva has. co

actavis, horizon teva valeant. pharma names that are loved and will stay loved as long as they keep growing faster than traditional companies at a time when growth remains hard to come by. >> irwin in new york. >> caller: good afternoon, jim. i'm a little confused and upset about novavax. back in the end of march around march 20th, the stock was trading about $9.70 a share. on march 25th they come out and anaunsed they are going to release 30 million shares roughly at $7.25 a share. the stock the next day dropped $2 and change to $7.50. why would they price a secondary offering $2 and change below that? >> that is a good idea. what they wanted to do was have it so everybody who bought on that deal made money. if you are someone who just got to that stock, you are thrilled with them and that's what they wanted to do. they felt you are already in it you made money, now let the new guys make money. a lot of guys price deals too high and that gets them hurt. i understood that. that is just a term of the way they do it.

that makes it potentially even more difficult for teva. the only thing we know right now is this could last a really long time if history is any guide. what we saw with allergan, this could take months to play out. >> that was a story that never ended. >> mylan real quick, last time meg was here mylan was up on the day. we said despite the fact it's had a big move to the upside it's going higher. here we are today and it's still cheap. and this story ain't over by the way. so you might get a little bit of back. i don't think you'll get that much. >> if mylan really doesn't want to be acquired it could also make a bid for something else potentially. >> which is right. exactly. i'm not as versed in the space as guy is. that's why i stick with the etfs. if you want to play this m&a trend, you want to be out of the ibb and into the xbi. that's the smaller cap names. that's where you'll get the bigger bang for the buck here. and great risk reward here. $2 to $3 risk for a big upside. >> meg, thank you. meg tirrell. >>> coming up next the latest

instead you chose to demonstrate the old teva is very much alive and becks questionsant teva's crediblehe nice part of the letter. what may be most important for those looking at what are they willing to accept here. they tell you, they say 25 times ebitda seems like a reasonable factor. that gets you to somewhere around $125 per share. ebitda is what they want to pay. they want everything taken off the table in terms of an anti-trust risk. oh, by the way, they want it in cash. you do that if you the teva and you are in business. mylan has anything at its disposal and the most talked about schticking. >> there were in that letter is a letter you would write someone, it was a poison pen letter. the nuttiness of the board and the corporate board. >> yesterday i tweeted and said it's i rarely seen anything like it. activists, dan lobe has written nasty letters. but from a corporate board, it was fascinating. >> when i met you, you seemed like a nice man. >> five pages. >> it was so personal so to make it so, we're never the price that you'd have to pay is so great, but we really hate you g

. >>, the teva is considering a bid for mylan.or said was trying to buy. neither side has agreed to anything. but then seeing them fall in this news than teva is apparently considering a bid for mylan. >> i'll pick it up from there. we've got a big jump in the shares of mylan on the back of that. it is the final count down. we're minutes away from the oil market closing out for the week at 2:30 p.m. eastern. crude is down on the day, but it is still up big on the week. boy, what a week it has been. we're currently at 55.59, down about 2% for wti crude. jackie. >> hey. good afternoon to you, mandy. it was a wild week for crude oil. selling pressure intensifying at the close. but what's going to happen next week? traders telling me we're setting up technically. i'll have that for you when we come back on "power lunch." but the m-class sees in your blind spot... pulls you back into your lane... even brakes all by itself. it's almost like it couldn't crash... even if it tried. the 2015 m-class. see your authorized dealer for exception

and periggo dropped 4% and teva added nearly 2%. >>> to the u.s. economy now where march durable good orders for big key ticket itemsupped 4% the largest increase in eight months but the rise was driven almost entirely by higher demand for defense, auto and aircraft orders: and an important measure of future investment fell 5%. more than estimates. the seventh straight monthly decline. >>> and that decline in business investment prompted a number of economists to trim forecast for firs growth which the government is due to report last week and that is the most widely followed measure of econoc health. but a comprehensive look at first quarter data over the past 30 years conducted by steve liesman shows there may be a big problem with the numbers. a trend that some economists have confirmed. >> the latest tracking data show another weak first quarter on tap. as low as 1% given what we know so far. will it be a coincidence it is another weak first quarter? cnbc went back to 1985 and did a detailed review of gross domestic data and the most growth in

at is that it is still below the $82 per share cash stock offer that teva has made for mylaxer an.et's move to today's overall action. four dow companies that reported earnings this morning, two of them are largely responsible for the drop you see now on your screen. travelers and dupont. they are the biggest point drags on the blue chip index accounting for about 30 negative dow points, that's more than half the current 67-point drop here. now 73-point drop. what is the trade? we bring in traders, elliott, i'm dying to get to you, but relate me get -- let me get to teddy first. we had ibm, dupont, travelers and united technology all with nothing really exciting on the earnings front, and that's what's dropping in this market here. what happens now to the dow as we head to the closing bell? >> well, i think, liz, and i mean, that addresses what the market did in the first quarter, what it's dope for most of april -- done for most of april, is we have a stock market in general that's pretty much priced to perfection, not a lot of room for error. the strong dollar, obviously, continu

they just hate teva. >> you said it. that's why i love having you here.'ll say things that i think but i won't say. >> that's mostly my job. i am your inner voice. >> i will say this. rob corey, the chairman of mylan who i said earlier is fairly free particularly one that starts with f. in that five page letter to teva there was not one expect people who read it said they were actually filled with them. >> the late george would have filled in the blanks. >> you're like the devil on tom hulse's shoulder!. >> yes. i was going to mention lobotomy. if i could some how get this part and put it right there, can you imagine what it would be like? it would be exan explosion. >> stay tuned for our live interview with dick costolo. futures still weak. squawk on the street is back in a minute. >>> time for the mad tashdash. four minutes until the opening bell. >> when you go to see dick costolo. >> when he comes to see us. >> when he comes to see us i want to tell him as bad as it is. how about a sichtuation where the cfo, there's a surprise loss and the justice dep

perrigo executives view that mylan stock price as inflated by a bid from teva. bid for mylan. mylan rejected that did and made a bid for perrigo. the stock still rose as they got these various offers. perrigo's executives think that the mylan offer has been inflated and is not going to stay at those levels because of teva's offer for that company. we have this three-way situation among these drug makers, and there's a lot of resistance on the part of them to accept these various bids. we will keep on top of that situation and let you know if and when perrigo goes public with that rejection. in the meantime i want to mention the european close and what we are seeing their and european stock markets. we did have a bit of a rally in european stocks today. we have german economic data. jumping to a 10 month high in april. you would not think as they greeted negotiations dragged on the greek stocks would be higher but they are heading for the biggest weekly advance in more than two months. it seems as though greece because of a holiday there might get more time in te

that could complicate their attempt to fen off teva's offer. they are urging the board to consider the proposal. taking a look at price action. you can see they're down about .7%. joining us to discuss the trade in bio tech is the head of sales and trade. thank you for joining us so early. we have already seen the massive run. a lot of that having to do with the mma we're seeing in this space. if you want to get in today do you buy the large caps that reported results last night or do you focus on the small to mid cap names that could be the next buyout target? >> i think that it's very difficult to focus in some of the smaller names if you're really unsure about this space. my lead is stick with the amgens, the names that really had significant out performance and continue to do well. we saw the rules. they were solid across the board. it paints a good outlook for what is yet to come for some of the larger bio tech names. the space has been on fire over the past five years. you know we really you know think that the growing here is just superi

and you can see it in fulfillment and we talked a lot about teva and talks in productivity.m the core business we see the retail market sim proving. we'll keep an eye on some of the new technology products. >> sean, we're going to leave it there, sean mill, who upgraded amazon. jp morgan is one that upgraded, was neutral for two years and decided today that it would upgrade. >> well melissa, i feel a little like an idiot myself because i've been neutral for the last two quarters, i thought last quarter was a head fake. now we're seeing it clearly is not. amazon is primed, pun intended to make money from all of these initiatives beyond just plain retail. i don't see anything to interrupt the upward trend of the stock right now. while i don't own it and i don't like buying rising stocks like this, i think it is something comfortable to own. >> i feel like a lot of this is because of the cloud business, aws. what if you wanted to invest in cloud, but did not want to buy into amazon? >> then you buy markt because of the growth in their cloud business. sacha nadella is knocking i

big mistake by teva. >> petrobras voting today on whether the release audible financials.ef international correspond nt is at petrobras'headquarterers. michelle. >> reporter: hey there, daiftd. when the sheet comes out tonight investors are looking at how big is the hole. it matters because they're the most indebted country in the entire world and the most major leverage accompany in the world by a long shot. this is one of the biggest if not the biggest financial scandal to hit brazil in its history which is a high bar to jump over in brazil. even though the share's trade, the adr trade at the stock exchange, make no mistake, they're controlled by the brazilian government. they control more than half of the voting shares and use the accompany as an arm of government policy. all of that coming home in the last year because in march, one of the accompany's directors was arrested for bribery. in september he started to sing and he told investigators for nearly 10 years nearly every contract was padded by at least 3% and then the money in that padding was used for bribery, ki

we'll have more in a moment. >>> coming up is it teva? technically retiring, sir. with a little help from my state farm agent i plan to retire in 15 years. wow! you're totally blindsiding me here. who's gonna manage your accounts? this is a devastating blow i was not prepared for. well, i'm gonna finish packing my things. 15 years will really sneak up on you. jennifer with do your exit interview and adam made you a cake. red velvet. oh, thank you. i made this. take charge of your retirement. talk to a state farm agent today. i care deeply about the gulf. i grew up in louisiana. i went to school here. i've been with bp ever since. today, i lead a team that sets our global safety standards. after the spill we made two commitments. to help the gulf recover and become a safer company. we've worked hard to honor both. bp has spent nearly 28 billion dollars so far to help the gulf economy and environment. and five years of research shows that the gulf is coming back faster than predicted. we've toughened safety standards too. including enhanced

teva pharmaceuticals is said to be weighing a takeover offer. teva has not made a formal approach, but mylan is aware of the company plus interest. a shakeup at jay-z's music streaming service, title. the company is replacing ceo andy chen with peter const at. peter was under seeing tidal under his previous owner. cuts have come just three weeks after tidal's star-studded launch. it has been an uphill battle for comcast is the telecom giant seeks approval for its $45 billion merger with time warner cable. the deal, first proposed last february, faced regulatory scrutiny from the department of justice and the fcc. sources told bloomberg that staff attorneys are nearing a recommendation to block the merger. what does the news mean for technology companies that depend on these internet service providers to reach their customers? r bloomberg west editor at law joins us. -- large joins us. susan crawford, thank you for joining us. what does this mean for innovation? susan: in order for anyone to reach a customer, to start a new business in the united

mylan had rejected that teva bid trying to acquire perrigo to make it a tougher target for teva.p track of all of that. you win the prize. this is an ongoing situation. this is not the less we will hear about it. olivia: investors excited for mylan to do the deal. thank you so much. julie hyman from our breaking news desk. ben bernanke. a new job. where is he going? matt: he is going to make even more money now. olivia: with pimco as a green -- with pimco as an analyst. matt: this guy, you can say what you want about his policies he worked his tail off. olivia: i thought you said -- i but you're going to say he's a sassy blogger. matt: the big money behind the big fight. two cable giants put aside differences to make it happen as they are going to get paid more money than ben bernanke will ever see in a lifetime. olivia: central bank and boxing. ♪ matt: time to bring you up-to-date on the top stories of the morning. prime minister shinzo abe is the first japanese leader to it dress a joint meeting of congress. aid is expected to echo president obama --abe is expected to echo the

and that a combination with have a -- with teva would face antitrust hurdles. it could create a powerhouse with more than $27 billion in revenue. and google is revamping its search service. the company boosting the ranking of mobile-friendly pages and analyzing what websites are suited for handheld devices. another top story were following at this hour -- an arrest made in connection with the 2010 flash crash. a u.k. traders accused of engaging in illegal bait and switch practices according to u.s. authorities. for more, i'm joined by senior markets correspondent julie hyman at the breaking desk. what did this traitor do that was so different than what is allowed through high-frequency trading -- what did this trait der do? julie: the man who was arrested as navinder sarao. he was arrested in the u.k., and he is a resident of that country. the department of justice is working out extradition. he has been charged with wire fraud, commodities fraud, commodities manipulation, and what is called spoofing. that would be to bid or offer with the intent to cancel the

elliott: we understand that teva's bid could be tabled as early as today.nly would it either biggest deal so far this year, it would created the understated -- undisputed king of generic drugs with revenues in the region of $30 billion a year. it has been speculated the two might get together. teva was to offset any drop of revenues from its multiple sclerosis drug facing competition this year. shares up in 3%. mylan in early trading, up 12%. brendan: thank you. it is the perfect different that special someone. a 100 carat diamond that is described as perfect. sotheby's will auction off the diamond in new york. it could bring $25 million. the diamond was mined -- [coughs] tom: you are gasping. olivia: brendan's wife is watching. brendan: weighed over 200 carats before was cut. those are your top headings. i need more money. tom: i am dr. tom. we welcome olivia sterns. how was the therapy going after our graph event? olivia: i feel a profound sense of loss. tom: fou4r carat loss? olivia: that was a 12 carat diam ond. i have done a lot of reporting on diamond

the red hot market for teva pharmacy

the red hot market for teva pharmacy

nothing says i'll beat your ass like a pink tank top and teva san dahls. cay has been trying to start a fight for like most of the video but we couldn't show you the whole individual why you know this guy what is his fraternity nick name natasha leggero. >> milwaukee's worst. >> sarah tiana. >> i think it's adell because he's chasing pavement. >> nice that's

. >>> generic drugmaker teva making an offer for a competitor today.d quarters in montgomery county. if if passes scrutiny by regulators the combined pharmaceutical powerhouse will dominate the market and they worry it will lead to higher generic prices. >>> and a warning about ticks. the first time researchers found the blood-sucking insects in every county. and they are the primary carrier of lyme's disease. the past five years, pennsylvania reported more infections than anywhere else in the united states. experts recommend wearing long sleeves and pants, using insect repellent and doing a full-body check after going outdoors. use fine-tipped tweezers to remove a tick that has bitten you. and please go to the doctor in symptoms develop. >>> a bensalem woman collared for alleged animal cruelty. saying inside of this home this morning they found 43 chihuahuas. the tenant on the 3500 block of morrow drive facing up to 100 charges. >>> tonight, the second part of my one-on-one with philadelphia archbishop charles chaput. we appreciated his hospitality an

however, if you take a look at some of the other plays people are looking at right now mylan, teva tevamly rejecting it. perrigo also part of that three-way that maybe transaction that could end up happening. it's all a big mess. but those biotech stocks certainly one of the big contributors to why the ibb and the overall sector and industry group is the worst performing on the s&p 500 today. back over to you. >>> speaking of a big mess corinthian college shutting down virtually overnight. it is leaving 16,000 students scrambling as their school shuts down. this just a week after the u.s. education department fining the company $30 million for misrepresenting job place of employment data. that stock is down 98% over the past year basically no longer a stock. let's brickng in herb greenberg, our friend. for years, you have been critical of many of these, not all, but many of these for-profit colleges. what is your take on corinthian? this is a significant blow to the entire industry. >> in the press release they put out, they talked about how they job place of employmentment rates were e

. >>> generic drugmaker teva mki an offer f a competitor tod. adheead quarters in montgomy county.pass scriny by rgutors the combined pharmtical perhouse will domina the market and they wrrit will lead to higher geric pres. >>nd a warning abo ticks. theirst time researche found the blood-suing insects in every county. andhey are the priry carrier o le's diseas the past fe years, pennsylvaa rerdo iftions th anywhere else in thunid states. expes recomnd wearing long sees and pas, using insect repellent d doi a full-body ce afr going outdoors. use fine-tipped tezers to remove a tick that has bitten you. adlease, go to t doctor in sytoms develop. >>> a bensalem wan collared for alleg animal cruelt syi inside of this home this mrng they found 43 chiahu. theenantn t 3500 block of morrow dri fing up to 100 chaes. >> toght, the second part of my one-oone wh philadelphia achbishop charles aput. we appreciated his hpitality ad ca away with alear intention that he does not acce the increasiny popular prayal ohim in eedia an arch conservive objecting t what se call the progressive views of pop

nothing says i'll beat your ass like a pink tank top and teva san dahls. to start a fight for like most of the video but we couldn't show you the whole individual why you know this guy what is

mylan is a generic drugmaker, as is teva.go sells storebrand versions of over-the-counter medications. none of this is a tax inversion deal because they're all incorporated outside the u.s. saving on taxes is not part of the motivation here. alix: thank you. to house passing two cyber security bills this week, and the bills will encourage companies to share cyber threat information with each other and the government. critics say they are quote surveillance bills in disguise. joining me to discuss is a republican congressman. he is a former undercover officer in the cia and senior advisor to a cyber security firm. thank you for joining us. guest: thanks for having me. alix: how do you convince companies to share data with each other and the government? guest: the key is liability protection. companies need to make sure there's a framework in which they can share this information with the federal government, and that will not cause undue pressure on their bottom line or their stock price. these two bills that we passed out of t

a rejection of a takeover bid from the israeli drugmaker teva for mylan.at they will not take anything seriously unless it is $100 a share. in the meantime, there is a takeover bid from the fellow drugmaker terror ago, which has also been rejected. the founder of the world's largest hedge fund firm says there's a lot to like about the chinese economy. guest: they have a lot of potential. as it flows to that other part of the government, in the end of it, i think they have a lot of potential. i remain bullish long-term. erik: ray dally oh founded the -- ray dalio sounded his firm in a two-bedroom apartment. and it will not -- your antitheft devices will not work if you leave the keys inside. people do not like to tell the police or insurance company and how careless they were. stephanie: our next guest worked in the high-yield market in since 1991 he has been running the $16 billion crescent capital, which invests in debt securities and is also co-owner of the milwaukee brewers. guest: great to be here. stephanie: you have been here many many times. what ar

mthey will be meeting -- teva will be meeting with mylan shareholders.rejected the deal today calling it too low. we want to bring you the latest on violence in baltimore. right now, hundreds of people are clashing with police after thousands gathered this morning following the death of freddie gray, mourning the death of a young black man who died of an unexplained spine injury while in police custody. julie: at this point we are still seeing some looting in the city of baltimore. earlier, we saw pictures of protesters, rioters, whatever you want to call them at this point, throwing bricks rocks other projectiles. that is video of what appeared to be an abandoned police car which was attacked by the protesters. we saw police vehicles set on fire. the baltimore police department says seven offices have been injured. various broken bones. one of them is unconscious or was when we got the last update. various places have been closed in baltimore. the university of maryland at baltimore, as well as the maryland institute college of art, there have been clos

take a look at teva. it is considering a bid. it jumped $4.32 in just a few minutes.sitive territory. wow. these are all according to store competitors. they had to deal with something else. mylan has made -- they are all intertwined. that will be one that continues to go up. melissa: nicole, thank you very much. 5574. it had quite a week here. closing down a little bit lower. so much volatility they are. breaking up the bundle. it seems more like a slight bend. you can buy a base set at channels. our very own jo ling kent is here. along with stock are in. also jonathan clonaid. give me some of the details. >> this is going from a buffet to almost all the car. two additional channel packs to that. what you see here are the basic channels. you also get some cable net. and then you add to channel packs to that. those are a lot of different kind of categories. melissa: i have some problems with this out of the date. first of all in that first group, that was not fox news channel. like everyone else in the world we have 6 billion channels in my house. we watch about 10. m